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Abstract
Background This study investigated the relationships
between histomorphological aspects of breast capsules,
including capsule thickness, collagen fiber alignment, the
presence of a-smooth muscle actin (a-SMA)–positive
myofibroblasts, and clinical observations of capsular
contracture.
Methods Breast capsule samples were collected at the
time of implant removal in patients undergoing breast
implant replacement or revision surgery. Capsular con-
tracture was scored preoperatively using the Baker scale.
Histological analysis included hematoxylin and eosin
staining, quantitative analysis of capsule thickness, colla-
gen fiber alignment, and immunohistochemical evaluation
for a-SMA and CD68.
Results Forty-nine samples were harvested from 41 pa-
tients. A large variation in histomorphology was observed
between samples, including differences in cellularity, fiber
density and organization, and overall structure. Baker I
capsules were significantly thinner than Baker II, III, and
IV capsules. Capsule thickness positively correlated with
implantation time for all capsules and for contracted cap-
sules (Baker III and IV). Contracted capsules had sig-
nificantly greater collagen fiber alignment and a-SMA–
positive immunoreactivity than uncontracted capsules
(Baker I and II). Capsules from textured implants had
significantly less a-SMA–positive immunoreactivity than
capsules from smooth implants.
Conclusion The histomorphological diversity observed
between the breast capsules highlights the challenges of
identifying mechanistic trends in capsular contracture. Our
findings support the role of increasing capsule thickness
and collagen fiber alignment, and the presence of con-
tractile myofibroblasts in the development of contracture.
These changes in capsule structure may be directly related
to palpation stiffness considered in the Baker score. Ap-
proaches to disrupt these processes may aid in decreasing
capsular contracture rates.
Level of Evidence III This journal requires that authors
assign a level of evidence to each article. For a full de-
scription of these Evidence-Based Medicine ratings, please
refer to the Table of Contents or the online Instructions to
Authors www.springer.com/00266.
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Introduction
Placement of a breast implant initiates a foreign body re-
sponse and ultimately results in the formation of a col-
lagenous capsule. One of the most common complications
associated with the presence of this collagenous capsule is
capsular contracture, which can result in pain, discomfort,
and distortion of the implant and the breast. The frequency
of the clinical manifestation of contracture varies dra-
matically in patients and may be influenced by a number of
exogenous factors, including surgical technique, pocket fit,
bleeding, trauma, implant fill, implant surface, incision
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location, placement relative to pectoralis major muscle,
infection or biofilm formation, breast reconstruction, ra-
diation therapy, implant compromise including gel migra-
tion [1–3], and others. With the many factors influencing
capsular contracture, identifying a relationship between
histological features of capsules and clinical presentation
of contracture may shed light on a common underlying
etiology or mechanism of contracture.
The foreign body response to an implanted device is
initiated by an inflammatory reaction followed by recruit-
ment of fibroblasts, which lay down collagen fibers, and
contractile myofibroblasts, which generate the force gen-
erally associated with contracture. At some point, myofi-
broblasts undergo apoptosis and contractile forces may
cease, whereas the collagen structure remains. Capsular
contracture results when the normal healing process fails or
when a pathological change is initiated by tissue trauma or
an exogenous trigger. The continued activity of fibroblasts
and myofibroblasts in a breast capsule may result in highly
aligned fibers and a rigid collagen capsule [4]. Highly
aligned collagen fibers would theoretically be associated
with a greater force of contracture when myofibroblasts are
stimulated to contract along uninterrupted parallel fibers
[5].
A number of surgical and prophylactic approaches have
been used to reduce the incidence of capsular contracture,
including surface texturing of the device, submuscular
implantation, and reduction of bacterial contamination
through nipple shields and antibiotic washes [6, 7]. The
current study was directed at elucidating the relationship
between capsular contracture, as measured by Baker score,
and histological features of the capsules, including the
presence of myofibroblasts and quantitative assessment of
collagen fiber alignment and capsule thickness.
Materials and Methods
Clinical Profile
Forty-nine tissue samples were harvested at the time of
implant removal from the anterior side of capsules sur-
rounding breast implants from 41 female patients under-
going breast implant replacement or revision surgery.
Specimens and clinical data were collected between 2009
and 2011 by Dr. Steven Teitelbaum after informed, written
consent was obtained in accordance with the Declaration of
Helsinki.
Clinical capsular contracture was scored preoperatively
using standard Baker score criteria. Baker scores were
determined by a single, well-experienced physician (Dr.
Steven Teitelbaum) using standard scoring criteria to
minimize the potential for interphysician variability. The
Baker assessment was done blinded to the data subse-
quently generated and all aspects of the technical assess-
ment were done in the absence of knowledge of the Baker
score, so that results in either direction were not influenced
by the clinical or laboratory results. Tissue samples were
collected as part of routine pathology assessment of cap-
sular tissue. Residual tissue from the pathology assessment
was utilized in this study. Inclusion criteria included any
female patient presenting to the practice of Dr. Steven
Teitelbaum for implant revision. Patients with implant
rupture were excluded from this study. Although Baker II
capsules are considered to be slightly contracted, for this
dataset the designation of an ‘‘uncontracted’’ capsule refers
to a Baker score of I or II, and the designation of a
‘‘contracted’’ capsule refers to a Baker score of III or IV.
Patient profile and implantation duration information are
summarized in Table 1 and Fig. 1.
Histology and Immunohistochemistry
Tissue samples were fixed in 10 % neutral-buffered formalin,
then processed and embedded in paraffin. Sectionswere cut at
5 lm for hematoxylin and eosin (Richard-Allan Scientific,
Kalamazoo, MI, USA) staining and immunohistochemistry.
Immunohistochemical evaluation was performed using
monoclonal antibodies specific for a-smooth muscle actin
(a-SMA), an indicator of myofibroblast presence (Clone
1A4, DAKO, Glostrup, Denmark) and for CD68 (Clone
KP1, DAKO, Glostrup, Denmark [antibody recognizes a
110-kDa glycoprotein expressed on monocytes and mac-
rophages]). All immunohistochemistry was performed us-
ing the EnVisionTM FLEX High pH visualization system
(DAKO, Glostrup, Denmark).
General characteristics of the histopathology of implant
capsules with different Baker scores were assessed visually
by review of hematoxylin and eosin-stained capsule sam-
ples. Capsules were classified into four categories: (1)
dense collagen, acellular or low cellular content (example
Fig. 4a), (2) dense collagen, moderate to high cellular
content (example Fig. 4b), (3) synovial metaplasia (ex-
ample Fig. 4c, d), or (4) loosely packed collagen (example
Fig. 4e, f).
Image Analysis
Sections were imaged at 94 and 920 magnifications and
analyzed using Nikon NIS Elements Advanced Research
software (Nikon, Melville, NY, USA).
Capsular thickness was measured from five evenly
spaced measurements of the capsule on a representative 94
magnification image as shown in Fig. 2. A capsule was
defined as the collagen fiber layer of tissue closest to the
implant surface.
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Alignment of capsular collagen fibers was assessed by
vector analysis measuring the extent to which the fibers
were parallel to the surface of the implant. A reference
vector was drawn parallel to the tissue-device interface on
a 920 magnification image of a hematoxylin and eosin-
stained section of the tissue. Twenty-five additional vectors
were drawn along individual collagen fibers and the angles
relative to the reference vector were measured. This was
repeated for a total of three images and 75 vector mea-
surements per sample. Vector angles were normalized to
the surface of the implant. The standard deviation of the
normalized vector angles was used as a measure of align-
ment, in which a highly aligned sample has a lower stan-
dard deviation of fiber angles (Fig. 3a), and a highly
unaligned sample has a higher standard deviation of fiber
angles (Fig. 3b).
Table 1 Patient data
Uncontracted Contracted Total
Baker I Baker II Baker III Baker IV
All implants, n (%) 6 (12.2) 12 (24.5) 28 (57.1) 3 (6.1) 49 (100.0)
Duration (implant to explant [years]), mean ± SD 6.1 ± 4.9 8.6 ± 4.9 9.9 ± 7.6 4.0 ± 1.7 8.7 ± 6.6
Implant surface, n (%)
Biocell 0 3 (6.1) 3 (6.1) 0 6 (12.2)
Siltex 1 (2.0) 1 (2.0) 1 (2.0) 0 3 (6.1)
Smooth 5 (10.2) 8 (16.3) 24 (49.0) 3 (6.1) 40 (81.6)
Implant placement, n (%)
Dual plane 0 1 (2.0) 3 (6.1) 0 4 (8.2)
Subglandular 3 (6.1) 6 (12.2) 9 (18.4) 0 18 (36.7)
Submuscular 3 (6.1) 5 (10.2) 16 (32.7) 3 (6.1) 27 (55.1)
Reason for implantation, n (%)
Reconstruction 0 0 1 (2.0) 0 1 (2.0)
Augmentation 6 (12.2) 12 (24.5) 27 (55.1) 3 (6.1) 48 (98.0)
Reason for explantation, n (%)
Contracture 0 4 (8.2) 24 (49.0) 3 (6.1) 31 (63.3)
Revision surgery 0 0 2 (4.1) 0 2 (4.1)
Complication with other breast 2 (4.1) 6 (12.2) 2 (4.1) 0 10 (20.4)
Size change or implant removal 4 (8.2) 2 (4.1) 0 0 6 (12.2)
0
2 3 4 5 6
Smooth
9 10
Duration of Implantation (Years)


















Fig. 1 Summary of patient implants with respect to time from
implantation to explant. Duration for smooth implants (n = 40)
ranged from 2 to 35 years with an average of 7.9 years, whereas
duration for textured implants (n = 9) ranged from 5 to 20 years with
an average of 11.7 years. Overall duration averaged 8.6 years for all
implants
Fig. 2 Measurement of capsular thickness. Capsular thickness was
measured by drawing a line to delineate the interface between capsule
and surrounding tissue where the capsule was defined as the layer of
collagenous tissue closest to the implant. Five measurements were
taken between the delineating line and the edge of the tissue
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To provide a rigorous exclusion of non-specific antibody
binding, immunostained samples were considered positive
for a-SMA if elongated and fibrous staining was visible in
C10 % of the capsule layer proximal to the implant. CD68-
stained samples were considered positive if cytoplasmic
staining was observed in[10 cells per 920 field.
Statistical Analysis
Statistical analysis for the comparison of capsule thickness
and fiber alignment by Baker score was performed using a
Kruskal–Wallis test. For p values of less than 0.05, a
Mann–Whitney U test was used to determine the sig-
nificance of the difference between the pairs of Baker score
groups. All other pairwise comparisons were performed
using the Mann–Whitney test. All statistical analyses for
immunopositive staining of a-SMA and CD68 were per-
formed using a v2 test. Linear regression analysis was used
to assess the impact of implantation time. A p value of less
than 0.05 was considered significant. All numerical data for
thickness and fiber alignment are presented as a
mean ± standard deviation unless otherwise noted. Out-
liers were included in all statistical analyses except linear
regression analysis. All statistical analyses were performed
using Minitab 15 Statistical Software (Minitab Inc., State
College, PA, USA).
In this study, the population was acquired based on
clinical need for breast revision surgery at a single clinical
site and as a result it does not represent a homogeneous
sample. Variables include implant type (smooth or tex-
tured), duration of implant placement, plane of implanta-
tion, and reason for explantation. Details of the patient
population are summarized in Table 1. Statistical analyses
accounted for the heterogeneity of the population and
whenever possible (based on number of events), patient
subsets were independently analyzed. Because the common
characteristic in all patients was implant revision in the
absence of implant rupture, these patients were grouped in
the overall analysis of Baker score and histomorphological
assessment. All patients underwent augmentation revision
with the exception of one patient who underwent recon-
struction revision. The patient who underwent reconstruc-
tion revision had the longest time from implantation to
revision (35 years).
Results
Capsule Architecture and Morphology
A large variation in histomorphology was observed be-
tween samples, including variations in cellularity, fiber
density, fiber organization, vascularization, and overall
structure. Capsules were generally found to have low cel-
lularity, although there was evidence of regions of in-
creased or concentrated cellularity in some cases at or near
the capsule-implant interface. Multiple layers of fibers of
differing fiber density and alignment were identified in a
number of samples, whereas other capsules were composed
of a single-collagen layer of variable density. In general,
the capsule region adjacent to the implant lacked vascu-
larization, although vascularization throughout the entire
capsule was evident in a small number of samples. Con-
tracted capsules were found to contain thick, dense bands
of highly aligned fibers (Fig. 4a, b, d), whereas uncon-
tracted capsules were composed of thin, loosely arranged,
multidirectional, string-like fibers (Fig. 4e, f). Morphology
consistent with synovial metaplasia was observed in some
samples and was characterized by a layer of synovial-like
cells arranged in a palisaded manner at the capsule-implant















































































































































































Fig. 3 a Distribution of vectors for a highly aligned capsule with a
standard deviation of 13.30 and b a highly unaligned capsule with a
standard deviation of 50.21. The distribution of vector angles is
representative of fiber alignment and is quantitated by the standard
deviation of vectors. If all fibers are parallel, all angles will be either
0 or 180 and the standard deviation of vector angles would be 0. If
none of the fibers are parallel, angles will be equally distributed
across all measures from 0 to 180
Aesth Plast Surg (2015) 39:306–315 309
123
Capsular Thickness
Capsular thickness ranged from 21 to 996 lm, with a mean
of 351.4 ± 215.4 lm. There was no significant difference
(p = 0.4777) in capsule thickness between smooth
(mean = 342.5 ± 216.0 lm, n = 40) and textured im-
plants (mean = 391.0 ± 220.7 lm, n = 9), although the
number of textured implants was limited and included both
Siltex and Biocell devices (no manufacturer information
was available for smooth implants). Uncontracted capsules
(Baker I and II, mean = 285.3 ± 270.3 lm) were sig-
nificantly thinner (p = 0.0111) than contracted capsules
(Baker III and IV, mean = 389.8 ± 169.4 lm, Table 2;
Fig. 5a). No significant difference in thickness was found
between Baker II, III, and IV capsules (p = 0.716, Fig. 5b).
However, Baker I capsules (mean = 91.5 ± 30.3 lm) were
found to be significantly thinner than Baker II
(mean = 408.6 ± 28.9 lm; p = 0.0012), III (mean =
393.4 ± 24.5 lm; p = 0.0002), and IV capsules (mean =
355.4 ± 17.9 lm; p = 0.0282). No significant difference in
thickness was found based on plane of implantation
(p = 0.152). Capsule thickness was positively correlated
with implantation time for all capsules (R2 = 0.151;
p = 0.0076; Fig. 6) and for contracted capsules alone
(R2 = 0.159; p = 0.026), but not for uncontracted capsules
alone (p = 0.296).
Collagen Fiber Alignment
The standard deviation of the vector angles of collagen
fibers with respect to the implant surface was used as a
measure of alignment and ranged from 13.3 to 50.2
Fig. 4 Hematoxylin and eosin
staining of human capsules
(magnification 920, scale bar
100 lm). All images are
oriented with the implant-tissue
interface in the lower portion of
the image. a Baker IV
contracted capsule with low
cellularity and thick dense
bands of highly aligned fibers
taken from a smooth silicone
implant after 3 years of
submuscular implantation.
b Baker IV contracted capsule
with increased cellularity and
thick dense bands of highly
aligned fibers taken from a
smooth silicone implant after
3 years of submuscular
implantation. c Baker II capsule
with morphology consistent
with synovial metaplasia taken
from a textured saline implant
after 10 years of dual plane
implantation. d Baker III
capsule with morphology
consistent with synovial
metaplasia taken from a smooth
silicone implant after 15 years
of submuscular implantation.
e Thin Baker I capsule with
loosely arranged fibers taken
from a smooth saline implant
after 3 years of submuscular
implantation. f Baker I capsule
with low cellularity and loosely
arranged fibers taken from a
smooth saline implant after
12 years of subglandular
implantation
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(mean = 25.9 ± 8.5), in which a lower standard deviation
indicates greater alignment. No significant difference
(p = 0.1631) in fiber alignment was observed between
capsules from smooth (mean = 24.8 ± 7.8) and textured
implants (mean = 30.7 ± 10.1), although this may simply
reflect the lower number of textured implants (n = 9)
analyzed as well as the mixture of both Siltex and Bio-
cell devices. Contracted capsules (mean = 23.8 ± 8.2)
showed significantly greater fiber alignment (p = 0.0068)
than uncontracted capsules (mean = 29.4 ± 8.1; Table 2;
Fig. 7a). Baker I capsules (mean = 30.3 ± 5.6) were
found to be significantly less aligned than Baker III
(mean = 24.5 ± 8.3; p = 0.0494) and Baker IV capsules
(mean = 17.9 ± 3.1; p = 0.0282), and Baker II capsules
(mean = 28.9 ± 9.5) were found to be significantly less
aligned than Baker IV capsules (p = 0.0364) as shown in
Fig. 7b. No significant difference in fiber alignment was
found based on plane of implantation (p = 0.418). Fiber
alignment was not correlated with time from implantation.
Myofibroblasts (a-SMA–Positive Immunoreactive
Staining)
Myofibroblasts were identified using immunohistochemical
staining for a-SMA, and, when present, were localized near
the tissue-device interface (Fig. 8a). One Baker II textured
sample was excluded from the analysis due to insufficient
tissue adherence to the slide. A significant difference
(p = 0.049) in a-SMA–positive immunoreactivity was
found based on contracture state, in which 39 % of con-
tracted capsules and 12 % of uncontracted capsules were
positive for a-SMA (Table 2). A lower percentage of
Baker I (17 %) and Baker II capsules (9 %) were positive
for a-SMA compared with Baker III (39 %) and Baker IV
capsules (33 %; Fig. 8b). All capsules from textured im-
plants were found to be negative for a-SMA, whereas 35 %
of capsules from smooth implants stained positive, which
was a statistically significant difference (p = 0.047;
Fig. 8c). The number of positive samples in the Baker I, II,
and IV groups were too small to allow for statistical ana-
lysis. No significant difference (p = 0.602) in a-SMA–
positive immunoreactivity was identified based on plane of
implantation.
Summary of Capsule Histopathology
The majority of Baker III and IV capsules exhibited a
dense acellular or low cellular content morphology,
whereas Baker I and II capsules exhibited predominantly
more loosely packed collagen. It is also interesting to note
that synovial metaplasia was more common in Baker I and
II capsules compared with Baker III and IV capsules.
Macrophages (CD68-Positive Immunoreactive
Staining)
Macrophages were identified using immunohistochemical
staining for CD68. No significant difference in CD68-
positive immunoreactivity was observed based on con-
tracture status (p = 0.737) or duration of implantation
(p = 0.5001). Analysis of CD68-positive immunoreac-
tivity was not possible by plane of implantation or Baker
Table 2 Summary of uncontracted versus contracted analysis of capsules
Capsule characteristic Uncontracted Contracted Uncontracted Contracted p valuea
Baker I Baker II Baker III Baker IV
Thickness (lm), mean ± SD 91.5 ± 30.3 408.6 ± 28.9 393.4 ± 24.5 355.4 ± 17.9 285.3 ± 270.3 389.8 ± 169.4 0.0111
Collagen fiber alignment (angle
SD), mean ± SD
30.3 ± 5.6 28.9 ± 9.5 24.5 ± 8.3 17.9 ± 3.1 29.4 ± 8.1 23.8 ± 8.2 0.0068
a-SMA, % of positive samples 17 9 39 33 12 39 0.049
Histopathology of capsule, % of samples
Dense collagen
Acellularb 43 55 75 67 50 81 0.001
Cellularc 14 18 14 33 17 10 NS
Synovial metaplasiad 29 9 7 0 17 6 NS
Loosely packed collagene 43 27 11 0 33 10 NS
NS not significant
a p value for comparison of uncontracted (Baker I and II) versus contracted (Baker III and IV)
b Example shown in Fig. 4a
c Example shown in Fig. 4b
d Example shown in Fig. 4c, d
e Example shown in Fig. 4e, f
Aesth Plast Surg (2015) 39:306–315 311
123
score due to limited sample groups. All textured implants
and 81 % of smooth implants were positive for CD68;
however, this difference was not statistically significant
(p = 0.174).
Discussion
The dataset in this study included 49 capsule samples with
Baker classification scores I through IV, and duration of
implant ranging from 2 to 35 years. Capsule tissues from
both smooth and textured implants were compared,
although the majority of the samples were derived from
smooth implants. All Baker IV capsules were from smooth
implants. Due to the small number of samples derived from
textured devices (n = 9) and the inclusion of two different
types of surface texture (Siltex and Biocell), no
conclusions could be drawn with respect to the impact of
each type of textured surface. Although the population
varies in age, implant type, reason for revision, and time to
revision, several common characteristics relating to in-
creased Baker score and capsule structure exist, including
capsule thickness, collagen structure, and staining of a-
SMA for myofibroblasts.
The alignment of collagen fibers was measured quanti-
tatively using a mathematically rigorous approach. Pub-
lished literature suggests that collagen fiber alignment is
routinely assessed in a qualitative manner by classification
of fibers as either aligned or unaligned, or by a descriptive
narrative of fiber orientation [8–13]. Figure 3 shows the
distribution of vector angles for the most aligned and the
least aligned samples in the dataset. In this study, fibers
were found to be progressively more aligned with in-
creasing Baker score. A statistically significant difference
in alignment was demonstrated between capsules when
grouped as uncontracted (Baker I and II) and contracted
(Baker III and IV), as well as when capsules were grouped
by individual Baker scores. This supports the theory that
alignment of collagen fibers is a key feature in capsular
contracture, and suggests that disruption of collagen fiber
alignment may decrease the incidence and severity of
capsular contracture [5]. Although capsules from textured
implants were less aligned than capsules from smooth
implants, this difference failed to reach statistical sig-
nificance, likely a result of the small number of samples
from textured implants and the presence of two different
types of textured surfaces. There was no correlation be-
tween fiber alignment and time from implantation for










































Fig. 5 Box plot of capsular thickness by level of contracture. The
whiskers represent the minimum and maximum values. The upper and
lower edges of the box represent the 25th and 75th percentile,
respectively, and the band represents themedian. aContracted capsules
(mean = 389.8 lm) are significantly thicker than uncontracted cap-
sules (mean = 285.3 lm; p = 0.0111). Three statistical outliers were
identified in the uncontracted group. Outliers included a Baker II
capsule from a smooth device that had been implanted for 10 years
(thickness = 996 lm), and twoBaker II capsules from textured devices
that had been implanted for 10 years (thickness = 736 and 723 lm).
b Baker I capsules are significantly thinner (mean = 91.5 lm) than
Baker II (mean = 408.6 lm; p = 0.0012), III (mean = 393.4 lm;




















Contracted Outliers – Uncontracted
Fig. 6 Capsular thickness was positively correlated with duration of
implantation for all capsules (R2 = 0.151; p = 0.0076) and for
contracted capsules (R2 = 0.159; p = 0.026), but not for uncontract-
ed capsules (p = 0.296). Solid data points are from textured implants
and open data points are from smooth implants. Statistical outliers
were only identified in the uncontracted group and were not included
in regression analysis. The sample identified at 35 years represents
the one patient with breast reconstruction and revision
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The diversity of the sample population was reflected in
the histomorphological variation in the capsule tissue,
which showed large differences in degree of cellularity,
fiber density and organization, vascularization, and gross
overall structure. Although no definitive pathological
identification was made, morphology consistent with syn-
ovial metaplasia was observed in several samples and has
previously been hypothesized to be a response to me-
chanical stress. The presence of synovial metaplasia-like
morphology is well documented [10, 13–16] and may serve
a lubricating function between tissue and implant [17].
Capsule thickness was found to correlate significantly
with contracture, in which Baker I capsules were found to
be significantly thinner than Baker II, III, and IV capsules.
This suggests that capsule thickening may contribute to the
transition from an uncontracted Baker I capsule to the
initial stages of Baker II contracture. Although the rela-
tionship between capsule thickness and contracture re-
mains to be fully elucidated, several studies have shown
that Baker III and IV capsules are thicker than Baker I and
II capsules [18–20]. Thickness for all capsules and con-
tracted capsules alone, but not for uncontracted capsules
alone, was found to increase with time from implantation
(Fig. 6), suggesting that fibroblasts continue to lay down
collagen fibers long after implantation.
Myofibroblasts are contractile fibroblasts that play an
active role in wound closure during healing and are com-
monly reported in capsule morphology [4, 21–23]. Ap-
propriately stimulated fibroblasts initially develop into
protomyofibroblasts, which have limited contractility, and
then into differentiated myofibroblasts, which are capable
of generating large contractile forces [21]. Immunopositive
staining for a-SMA, a marker for differentiated myofi-
broblasts [24–26], demonstrated localization of myofi-
broblasts near the capsule-device interface, consistent with
the findings of Hwang et al. [4]. A significantly higher
percentage of contracted capsules as compared with un-
contracted capsules were found to be immunopositive for
myofibroblasts. This is consistent with the hypothesis that
myofibroblasts play an active role in capsular contracture
[4, 21].
Samples from textured implants were all found to be
negative for myofibroblasts, suggesting that a textured
surface influences capsular contracture by reducing the
presence of myofibroblasts in the capsular tissue. Although
the mechanism by which this reduction of myofibroblasts
takes place has yet to be elucidated, the morphology of the
three Baker IV capsules in this study may provide clues. Of
the three capsules, only one was found to be im-
munopositive for a-SMA. The a-SMA–positive Baker IV
capsule showed increased cellularity and vascularization
and was histomorphologically distinct from the other two
a-SMA–negative Baker IV capsules. Myofibroblasts are
well documented to be present during the active period of
wound healing but diminish as wounds progress to a more
mature state [24]. It may be that the Baker IV capsules that
did not show myofibroblast presence had progressed to a
more mature state. In this case, a contractile force may be
exhibited early by stimulated myofibroblasts resulting in
contracture, which is then physically maintained by virtue
of the deposition of a dense collagen capsule which retains
the physically contracted state. The diminished presence of
myofibroblasts and a-SMA staining in the presence of
contracture may then be expected much like what has been
observed in wound healing and scar formation where my-
ofibroblasts undergo apoptosis in the later stages [24]. It
0
Uncontracted Contracted
























































Baker I Baker II Baker III Baker IV
Fig. 7 a Box plot of collagen fiber alignment by level of contracture.
The whiskers represent the minimum and maximum values. The
upper and lower edges of the box represent the 25th and 75th
percentile, respectively, and the band represents the median.
Contracted capsules (mean = 23.8) had fibers that were significantly
more aligned than uncontracted capsules (mean = 29.4; p = 0.0068).
b Fiber alignment increased with increasing Baker score (mean Baker
scores: I = 30.3, II = 28.9, III = 24.5, and IV = 17.9). One outlier
capsule was identified in the Baker II/uncontracted group from a
textured device that had been implanted for 10 years (SD = 50.2).
Three outliers were identified in the Baker III/contracted group,
including a capsule from a textured device that had been implanted
for 10 years (SD = 43.3), a capsule from a smooth device that had
been implanted for 9 years (SD = 41.1), and a capsule from a smooth
device that had been implanted for 2 years (SD = 39.32).
*Represents statistical outliers
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remains to be determined if the lack of myofibroblasts in
capsules from textured implants is due to a more rapid
progression of the capsule to a mature state or due to a
reduction in myofibroblast differentiation from fibroblasts.
Fibrocyte-stimulating cytokines released by inflamma-
tory cells are known to play an important role in regulating
fibroblasts and modulating collagen deposition during
wound healing. CD68-positive immunoreactivity was used
as a marker for inflammatory infiltration. Although Kamel
et al. [9] have suggested an inverse relationship between
CD68-positive macrophages and the degree of contracture,
our results revealed no relationship with state of contrac-
ture or implant surface. These results suggest that the role
of inflammation in capsule formation is decidedly more
complex than the simple presence or absence of macro-
phages [27].
The nine samples from textured implants in this study
were derived from two different manufacturers, with each
texture having a unique microscopic surface structure and
interaction with tissue [5, 28]. Due to the limited sample
size, textured sample data were pooled as in previously
published reports [4, 10, 13, 20, 29]. This may, in part,
have contributed to the lack of robust effects of texture on
capsule formation. Despite these pooled samples, a sig-
nificant difference in the presence of a-SMA–positive
myofibroblasts was identified between capsules from
smooth and textured implants, indicating that myofibrob-
lasts play an important role in the biological effect of
texture on capsular contracture.
Baker score, although subjective, has been utilized as a
common way to assess the status of breast implants and the
degree of capsule contracture. One of the critical compo-
nents of the Baker classification is the degree of firmness of
the breast. A Baker I score is considered to be normally
soft, Baker II is considered to be mildly or a little firm,
Baker III is considered to be firm or moderately firm with a
beginning of distortion, and Baker IV is considered to be
firm and quite distorted in shape. The basis of these
changes is reflected in this study in the histomorphological
changes observed with increasing Baker score. Although
the assessment of breast firmness may be quite variable
between physicians and between patients with different
size and shaped breasts, and a different skin and tissue
coverage, the data presented here demonstrate common
histologic changes that correlate with and potentially in-
fluence the degree of firmness. In particular, capsule
thickness and collagen fiber orientation independent of
time may be considered to affect firmness and Baker score.
Furthermore, the increased frequency of a-SMA–positive
capsules indicative of myofibroblast activation also sup-
ports an additional component of increased firmness, since
myofibroblast activation is associated with contracture of
scar tissue and capsules.
Conclusion
The aimof this studywas to investigate the nature of capsular
contracture as it relates to collagen fiber alignment, capsule
thickness, and the presence of a-SMA–positive myofibrob-
lasts and CD68-positive macrophages. The histomorpho-
logical diversity observed in these capsules highlights the
challenges of identifying mechanistic trends in capsular
contracture, which may be influenced by the diversity of the
patient population, the surgical procedure, and timing of the
explant. Clinical studies controlling formany of these factors
often include only relatively short time periods and fre-
quently lack histological data. Despite the significant di-
versity of the sample population, this histological
characterization of samples ranging from 2 to 35 years of
implant duration demonstrated a positive quantitative asso-
ciation between collagen fiber alignment and Baker score, a
positive quantitative association between capsule thickness
and Baker score, as well as a correlation of a-SMA–positive
myofibroblasts with contracture and implant surface texture.
These findings indicate that the mechanism of capsule
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Fig. 8 a-Smooth muscle actin (a-SMA) staining of human capsules
(magnification 94, scale bar 500 lm). a Representative a-SMA–
positive staining where myofibroblasts can be seen localized to the
tissue-device interface. b Percentage of capsules a-SMA–positive for
myofibroblasts by Baker score. c Percentage of capsules a-SMA–
positive for myofibroblasts by implant surface
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contracture and capsule stiffness involves both capsule
thickening, which may increase over time, and alignment of
collagen fibers as well as the presence of contractile myofi-
broblasts. These changes were common in spite of the di-
verse population and individually unique histological
variations in capsule tissue from one patient to another.
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